We serve Chemical Name:ethyl 3-hydroxy-3-methylbutyrate CAS:18267-36-2 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:ethyl 3-hydroxy-3-methylbutyrate
CAS.NO:18267-36-2
Synonyms:Ethyl 3-hydroxy-3-methylbutyrate;3-hydroxy-3-methyl-butyric acid ethyl ester;EINECS 242-147-5;ethyl-3-hydroxy-3-methylbutanone;ethyl 3-hydroxyisovalerate
Molecular Formula:C7H14O3
Molecular Weight:146.18400
HS Code:2918199090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:215.7ºC at 760mmHg
Density:1.007g/cm3
Index of Refraction:1.433
PSA:46.53000
Exact Mass:146.09400
LogP:0.71050
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like Ethyl 3-hydroxy-3-methylbutyrate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,ethyl 3-hydroxyisovalerate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,ethyl-3-hydroxy-3-methylbutanone Use and application,Ethyl 3-hydroxy-3-methylbutyrate technical grade,usp/ep/jp grade.
Related News: The outlook for a cure is clouded with theoretical uncertainties and high-profile failures. Pharmaceutical giants including Johnson & Johnson, Merck and Pfizer have ditched their projects on unsatisfactory data. ethyl 3-hydroxy-3-methylbutyrate manufacturer The government will also send a charter flight with an Air New Zealand crew to repatriate up to 300 citizens in Wuhan. ethyl 3-hydroxy-3-methylbutyrate supplier The government will also send a charter flight with an Air New Zealand crew to repatriate up to 300 citizens in Wuhan. ethyl 3-hydroxy-3-methylbutyrate vendor The outlook for a cure is clouded with theoretical uncertainties and high-profile failures. Pharmaceutical giants including Johnson & Johnson, Merck and Pfizer have ditched their projects on unsatisfactory data. ethyl 3-hydroxy-3-methylbutyrate factory The entire set of results “strongly support” the Darzalex-Rd combo as a new standard of care for newly diagnosed, transplant-ineligible multiple myeloma patients, Thierry Facon, M.D., an investigator of the MAIA trial, said in a statement.
